NCT06164327 2023-12-11
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 1 Unknown
Clinical Trials
51 trialsNCT05290090 2023-10-17
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05887726 2023-07-27
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05940051 2023-07-11
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05923879 2023-06-28
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Ruijin Hospital
Unknown
NCT05179733 2023-05-23
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
Phase 3 Unknown
NCT05784987 2023-03-27
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT05777369 2023-03-21
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT05498259 2023-02-03
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05575973 2022-10-12
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
Phase 2 Unknown
NCT03736616 2022-07-22
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
Phase 2 Unknown
NCT04058470 2022-04-14
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT05200312 2022-03-11
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05186558 2022-03-07
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT03837873 2022-01-26
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT03949062 2021-02-17
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04025593 2020-11-19
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04622579 2020-11-10
R2DLBCL80
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT04425824 2020-06-16
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
ChineseAMS
Phase 2 Unknown
NCT04432402 2020-06-16
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT02951728 2020-03-11
DR-CHOP
Ruijin Hospital
Phase 1/2 Unknown
NCT02060656 2019-09-19
LEGEND
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT03777085 2019-05-30
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT01670370 2019-02-15
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT02767674 2019-01-03
Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Unknown
NCT02753647 2017-11-14
Chidamide Plus R-CHOP in Elderly DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT03018626 2017-07-28
R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT02871869 2017-07-17
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
Xinjiang Medical University
Phase 2/3 Unknown
NCT03022123 2017-01-16
The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma
Hebei Medical University Fourth Hospital
Phase NA Unknown
NCT01653067 2016-10-27
STORM
University Hospital Heidelberg
Phase 2 Unknown
NCT01279902 2016-07-26
Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL
Asan Medical Center
Phase 2 Unknown
NCT02792491 2016-06-09
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
Pusan National University Hospital
Phase 2 Unknown
NCT02772822 2016-05-16
A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
Sinocelltech Ltd.
Phase 3 Unknown
NCT02758925 2016-05-04
CyBeR-Lymph
University Hospital, Caen
Phase 2 Unknown
NCT02753062 2016-04-27
PTLD
Asan Medical Center
Phase 2 Unknown
NCT02428751 2015-11-18
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
Sun Yat-sen University
Phase 3 Unknown
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005959 2013-12-04
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00028717 2013-09-17
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00974792 2013-08-26
Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01278602 2013-03-05
R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma
Fudan University
Phase 2 Unknown
NCT01009970 2011-10-13
Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 2 Unknown
NCT01181999 2011-09-22
Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
Chonnam National University Hospital
Phase 2 Unknown
NCT00499018 2011-02-15
DLCL04
Fondazione Italiana Linfomi - ETS
Phase 3 Unknown
NCT01066429 2010-02-12
DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma
Hospital Universitario Principe de Asturias
Phase 2 Unknown
NCT00689845 2009-07-08
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase NA Unknown
NCT00069966 2009-07-07
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
National Cancer Institute (NCI)
Phase 2 Unknown